09:01 AM EDT, 07/17/2024 (MT Newswires) -- Longeveron ( LGVN ) said Wednesday it received fast track designation from the US Food and Drug Administration for its investigational cell therapy Lomecel-B as treatment for mild Alzheimer's. Shares of the company were up 18% in recent Wednesday premarket activity.

The designation is the fifth special regulatory designation given to Lomecel-B, alongside the regenerative medicine advanced therapy designation for the same indication, Longeveron ( LGVN ) said.

Price: 4.1700, Change: +0.65, Percent Change: +18.47